FoundationOne®CDx is approved as the companion diagnostic for TABRECTA
FoundationOne®CDx is FDA approved as the companion diagnostic for detecting mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) in metastatic non-small cell lung cancer (mNSCLC) to help identify patients who are eligible for treatment with TABRECTA™ (capmatinib) 150 mg, 200 mg tablets, an FDA-approved targeted therapy.